Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors.
In 14 patients (4 males and 10 females) with systemic hypertension plasma and erythrocyte lipid peroxides, plasma and erythrocyte catalase activity, plasma glutathione S-transferase (GST) activity, blood reduced glutathione (GSH) content and erythrocyte oxidant stress were investigated. All parameters were performed after clinical examination and then the patients were assigned to receive ACE inhibitor therapy, captopril (25-50 mg given twice per day) or enalapril (10-40 mg given twice per day). After six months the determination of lipid peroxides and antioxidative factors was repeated. At the beginning of the study both treated groups showed significantly higher plasma lipid peroxides compared to the control group. Both used ACE inhibitors produced significant decrease of plasma lipid peroxides after six months. Blood GSH content was also significantly higher in both patient groups before the treatment compared to the controls. Neither captopril nor enalapril produced any significant effect on GSH. Initial values of plasma GST activity in the patients were similar to the control group and did not significantly change after six month treatment. The patients assigned to receive enalapril showed significantly enhanced initial plasma catalase activity according to the controls. After six months treatment both ACE inhibitors significantly decreased plasma catalase activity. Erythrocyte lipid peroxides, erythrocyte catalase activity and oxidant stress of erythrocytes in both groups studied neither differ significantly at initial time of investigation according to the control group nor during or after six month treatment.
Djordjević
V B
VB
Institute of Biochemistry, Faculty of Medicine, Nis, Yugoslavia.
Pavlović
D
D
Pejović
M
M
Cvetković
T
T
Lecić
N
N
Deljanin-Ilić
M
M
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use; D002374:Catalase / Q000097:blood*; D004656:Enalapril / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005978:Glutathione / Q000097:blood*; D005982:Glutathione Transferase / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008054:Lipid Peroxides / Q000097:blood*; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D008054:Lipid Peroxides; D004656:Enalapril; D002216:Captopril; D002374:Catalase; D005982:Glutathione Transferase; D005978:Glutathione